| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | VeraDermics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $263.24M | Series C | 10/16/2025 | $151M | $306.13M | $1.27 | SR One, Viking Global Investors, Marshall Wace, Invus, Abrdn, Columbia Threadneedle Investments, Infinitium, LifeSci Venture Partners, Longitude Capital, Suvretta Capital Management, Surveyor Capital | ||||
 | Zenas BioPharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Zus Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | 3T Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Aera Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | AQEMIA | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Athelas | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $365.02M | Series B-2 | 10/3/2023 | $60M | $969.5M | $103.96 | Undisclosed Investors | ||||
 | BigHat Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $104.3M | Series B | 7/20/2022 | $80M | $249.63M | $9.24 | Section 32, Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, Andreessen Horowitz, 8VC, AME Cloud Ventures | ||||
 | Biolinq | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $275.18M | Series C-1 | 4/22/2025 | $100M | $397.31M | $1.05 | Alpha Wave Ventures, RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, Features Capital | ||||
 | Centrexion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $569.49M | Series D | 9/30/2019 | $90.34M | $327.06M | $1.80 | New Enterprise Associates, Eli Lilly, Exome Asset Management, Quan Capital, ArrowMark Partners, Clough Capital Partners L.P., InterWest Partners, 6 Dimensions Capital, Efung Capital | ||||
 | Cohere Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $196.1M | Series C | 5/14/2025 | $90M | $724.92M | $13.71 | Temasek, Deerfield Management, Define Ventures, Flare Capital Partners, Longitude Capital, Polaris Partners | ||||
 | Emulate | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $205.31M | Series F-1 | 3/8/2024 | $54.02M | $132.81M | $1.17 | Undisclosed Investors | ||||
 | Frontier Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.5M | Series C | 6/25/2024 | $100M | $438.18M | $2.34 | Deerfield Management Company, Droia Ventures, Galapagos NV, DCVC, MPM Capital, RA Capital Management, Deep Track Capital, ArrowMark Partners | ||||
 | HealthEdge | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Latigo Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $287.9M | Series B | 3/17/2025 | $150M | $525.73M | $1.57 | Blue Owl Capital, Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, Kern Capital, Westlake Village BioPartners, Foresite Capital, 5AM Ventures, Alexandria Venture Investments | ||||
 | Musely | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $28.08M | Series B | 9/12/2014 | $20M | $117.1M | $12.56 | SharesPost and several undisclosed investors | ||||
 | Nimble Rx | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Paradromics | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $105M | Series A-3 | 2/12/2025 | $15.78M | $499.98M | $1.17 | NEOM Investment Fund, Kaleida Capital, Leo Lion, Prime Movers Lab, Wescott Investment Group, Dolby Family Ventures, Synergy Ventures, Pureland Global Venture, IT-Farm, Alpha Edison, Green Sands Equity | ||||
 | Pathos | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $469.3M | Series D | 5/15/2025 | $331.82M | $1.6B | $7.55 | Undisclosed Investors | ||||
 | Pendulum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.76M | Series C | 6/30/2023 | $64M | $308.05M | $3.24 | Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, Fonterra | ||||
 | Prellis Biologics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Seaport Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $330.1M | Series B | 10/21/2024 | $226M | $725.46M | $14.92 | General Atlantic, T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs, CPP Investments, ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, PureTech Health | ||||
 | SPR Therapeutics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $104.49M | Series D-1 | 2/1/2024 | $25.64M | $263.67M | $27.44 | Revelation Partners, RC Capital, Mutual Capital Partners | ||||
 | Synthego | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $415.07M | Series E | 2/17/2022 | $144.17M | $1.3B | $10.78 | Perceptive Advisors, SoftBank, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund, Chimera Abu Dhabi, Wellington Management, RA Capital Management, Moore Strategic Ventures | ||||